| Expression pattern: |
DN |
| Associated gene: |
CypD, TRAP1, HSP90 |
| Associated microRNA: |
- |
| Biological function: |
Suppresses tumor cell proliferation; induces mitochondrial apoptosis; increases sensitivity to bortezomib; inhibits tumor growth in vivo via EV delivery. |
| Molecular mechanism: |
Encodes peptide circp53-209aa that binds CypD, disrupts the CypD/TRAP1/HSP90 complex, activates CypD isomerase activity, triggers mPTP opening, leading to mitochondrial apoptosis; can be delivered by engineered EVs for tumor targeting. |
| Biological pathway or process: |
mitochondrial function (other); apoptosis (promotes); p53 signaling (promotes); proliferation (inhibits) |
| Detected method: |
Q
H
S
|
| Validation methods: |
Back-Splice Junction PCR / divergent primers PCR; RNase R Treatment; Sanger Sequencing; RT-qPCR; RNA-seq; ISH (In Situ Hybridization); Clinical Sample Validation; Cohort Study; Survival Analysis; Transfection; MTT; EdU Staining; TUNEL; CCK8; Western Blot; Co-IP; IF (Immunofluorescence); ELISA; In Vivo Animal Model; H&E Staining; Bioinformatics Analysis |
| Clinical significance: |
Higher circp53 expression is associated with longer overall survival in MM; circp53 is decreased in MM tissues and blood and in CRC tissues versus normal controls. |
| Description: |
TP53-derived circp53 (hsa_circp53_0041947) is down-regulated in MM (and reduced in CRC tissues). Increasing circp53 suppresses proliferation and induces mitochondrial apoptosis by encoding the peptide circp53-209aa, which binds CypD and disrupts the CypD/TRAP1/HSP90 complex to trigger mPTP opening. Engineered EVs delivering circp53 show tumor-targeted inhibitory effects in MM and CRC models, and higher circp53 expression in MM correlates with longer overall survival. |
| Confidence score: |
0.8557 |